ALS is a rare neurodegenerative disease with fatal outcome. The lack of treatments, the high impact on quality of life of patients and families, the strong emotional effect on the society and the related health care costs have prompted, in the last decade, most international scientific institutions to focus on this disease. TRANS ALS consortium embeds all these aspects.
The mechanisms of the disease remain largely unknown, while treatments able to halt or at least significantly slow its course are urgently needed.
Current literature suggests that focusing on cellular, molecular and clinical signatures is mandatory to identify genes and modifier factors influencing the risk of disease, and for providing new prognostic stratification of patients and therapeutic targets.
To achieve this objective, we have created a wide and complementary Consortium that, aggregating high-level expertise in basic neuroscience, clinics, genetics, and nanotechnology will implement translational and personalized management of ALS patients and at asymptomatic mutation carriers at risk of disease. Pillar of the Consortium is the joint within Regione Lombardia of 19 clinical centers, 7 basic neuroscience laboratories with extensive experience in the field of ALS research, and the Nanostructured Materials laboratory at the Polytechnic of Milan University, with the overall aim to deepen the existing knowledge of disease mechanisms in ALS and to address still unresolved clinical needs.
Consortium: 21 partners from 1 country
Coordinator of the project: Fondazione IRCCS Istituto Neurologico Carlo Besta (FINCB), Italy
Funding programme: Fondazione Regionale per la Ricerca Biomedica (FRRB)
Project start: 1st February 2017
End date for the project: 31st July 2020